<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>丰硕创投 | wechat-feeds</title><link>http://MzA3ODc3MDk2Nw.favicon.privacyhide.com/favicon.ico</link><description>聚焦医药投研</description><managingEditor> (hellodword)</managingEditor><pubDate>Tue, 01 Jun 2021 18:03:05 +0800</pubDate><image><url>http://MzA3ODc3MDk2Nw.favicon.privacyhide.com/favicon.ico</url><title>丰硕创投 | wechat-feeds</title><link>http://MzA3ODc3MDk2Nw.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>PI3Kδ抑制剂优于BTK抑制剂？！</title><link>https://mp.weixin.qq.com/s/I38whBv5fuqdVlNpXVXqOA</link><description></description><content:encoded><![CDATA[PI3Kδ抑制剂优于BTK抑制剂？！]]></content:encoded><pubDate>Tue, 01 Jun 2021 16:42:33 +0800</pubDate></item><item><title>盘点拿中国临床数据申报美国上市的企业</title><link>https://mp.weixin.qq.com/s/yuRVoqKc0c9mJeRC5UQhJQ</link><description></description><content:encoded><![CDATA[盘点拿中国临床数据申报美国上市的企业]]></content:encoded><pubDate>Wed, 26 May 2021 10:57:51 +0800</pubDate></item><item><title>AI公司Recursion：引领图像识别药物开发新潮流</title><link>https://mp.weixin.qq.com/s/NthuO5n1UyUnwbiVO3beCQ</link><description></description><content:encoded><![CDATA[AI公司Recursion：引领图像识别药物开发新潮流]]></content:encoded><pubDate>Tue, 25 May 2021 11:20:10 +0800</pubDate></item><item><title>PI3Kδ靶点—国内药企雄起的机遇</title><link>https://mp.weixin.qq.com/s/ygFU9eNrMWtI4hewjyUrpA</link><description></description><content:encoded><![CDATA[PI3Kδ靶点—国内药企雄起的机遇]]></content:encoded><pubDate>Mon, 24 May 2021 17:12:08 +0800</pubDate></item><item><title>作用于表观遗传学的共价药物---menin抑制剂</title><link>https://mp.weixin.qq.com/s/ivFhVwl6lpGc-O-tlxVrng</link><description></description><content:encoded><![CDATA[作用于表观遗传学的共价药物---menin抑制剂]]></content:encoded><pubDate>Tue, 18 May 2021 15:55:33 +0800</pubDate></item><item><title>手握重磅IL-4Rα药物的康诺亚，成立5年即IPO</title><link>https://mp.weixin.qq.com/s/8c4L9xHCQgbzRgu0gNT98Q</link><description></description><content:encoded><![CDATA[手握重磅IL-4Rα药物的康诺亚，成立5年即IPO]]></content:encoded><pubDate>Tue, 11 May 2021 16:32:57 +0800</pubDate></item><item><title>从销售数据看细胞与基因治疗的竞争格局</title><link>https://mp.weixin.qq.com/s/HIwsVnyg-r-1qhZkhhVc6w</link><description></description><content:encoded><![CDATA[从销售数据看细胞与基因治疗的竞争格局]]></content:encoded><pubDate>Mon, 10 May 2021 16:58:26 +0800</pubDate></item><item><title>靶向IL-4Rα，潜在百亿美元市场的重磅药物</title><link>https://mp.weixin.qq.com/s/BFjPOMV9FnjEnf3ZLVRMZA</link><description></description><content:encoded><![CDATA[靶向IL-4Rα，潜在百亿美元市场的重磅药物]]></content:encoded><pubDate>Fri, 07 May 2021 14:25:35 +0800</pubDate></item><item><title>胃癌一线疗法迎来新格局</title><link>https://mp.weixin.qq.com/s/gnsbqH9yhOgO06vANez7Xw</link><description></description><content:encoded><![CDATA[胃癌一线疗法迎来新格局]]></content:encoded><pubDate>Thu, 06 May 2021 15:15:54 +0800</pubDate></item><item><title>开发CAR-T治疗实体瘤的科济药业</title><link>https://mp.weixin.qq.com/s/Ij1ns3Lfrg9VrKslBdAcDA</link><description></description><content:encoded><![CDATA[开发CAR-T治疗实体瘤的科济药业]]></content:encoded><pubDate>Mon, 26 Apr 2021 16:19:23 +0800</pubDate></item></channel></rss>